Clinical trials: Sexually Transmitted Infections
GENITAL HERPES
Efficacy of Oral Famciclovir 125mg Comparing to Aciclovir 200 mg Treatment in Patients With Active Recurrent Genital Herpes
Recurrent genital herpes is a commonly occurring sexually transmitted disease caused by herpes simplex virus (HSV). There are effective oral prescription antiviral medicines available to reduce the discomfort of symptoms, such as…
- Trial name
- NCT01281007
- Testing
- Famciclovir, Aciclovir
- Where
- 9 sites in Brazil
- Volunteers
- 150 people
- Sponsor
- EMS
Sexually Transmitted Diseases
A Trial to Compare Antibacterial vs. Placebo Mouthwash to Reduce the Incidence of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men (MSM) Taking HIV Pre-Exposure Prophylaxis (PrEP)
The study involves a randomized placebo controlled trial that aims to assess if a mouthwash (Listerine cool mint, LCM) is able to reduce the cumulative incidence of gonorrhoea (Ng), chlamydia (Ct) and syphilis in men who have sex…
- Trial name
- PReGo (NCT03881007)
- Testing
- Mouthwash with LCM
- Where
- Belgium
- Volunteers
- 343 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
HIV Infections
BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada
The purpose of this study is to evaluate the safety, tolerability and antiviral effects of atazanavir (ATV) plus ritonavir (RTV) versus a combination drug of lopinavir (LPV) plus RTV.
- Trial name
- NCT00272779
- Testing
- ATV, RTV, Tenofovi-Emtricitabine (TDF/FTC) tablet
- Where
- 79 sites in United States, Argentina and 27 more
- Volunteers
- 1,057 people
- Sponsor
- Bristol-Myers Squibb
Urogential Chlamydia Trachomatis Infection
Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin
Evaluate the clinical efficacy and safety of WC2031 200 mg tablets taken orally once a day for 7 days versus Vibramycin (doxycycline) 100 mg capsules taken orally twice a day for 7 days, for the treatment of uncomplicated…
- Trial name
- NCT01113931
- Testing
- Doxycyline Hyclate tablet, Vibramycin (doxycyline hyclate) capsule
- Where
- 43 sites in United States
- Volunteers
- 495 people
- Sponsor
- Warner Chilcott
Human Immunodeficiency Virus, Coronary Artery Disease
Effect of Evolocumab on Coronary Endothelial Function
The investigators propose a pilot study using (1) MRI to assess coronary artery endothelial function, (2) brachial ultrasound to assess systemic endothelial function, (3) serum markers of inflammation and of endothelial cell…
- Trial name
- EVOLVE (NCT03500302)
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Johns Hopkins University
Human Immunodeficiency Virus, Risk Reduction
Building Mobile HIV Prevention and Mental Health Support in Low-resource Settings
The purpose of this research study is to provide help and support for mental health and human immunodeficiency virus (HIV) risk reduction among Romanian gay and bisexual men.
- Conditions
- Human Immunodeficiency Virus, Risk Reduction, Alcohol Abuse, Depression, Anxiety
- Trial name
- NCT03912753
- Testing
- Comunică, Education Attention Control
- Where
- Romania
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Columbia University
HIV Infection, Hepatitis B
Comparison of Three Hepatitis B Vaccination Regimens in HIV-Positive Youth
Hepatitis B is a contagious virus that can damage a person's liver. It can be prevented by vaccination, but for many HIV-positive people, the vaccines do not help them achieve adequate protection against this virus.
- Trial name
- NCT00106964
- Testing
- Engerix-B 20 mcg, Engerix-B 40 mcg, Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg
- Where
- 11 sites in United States, Brazil and 1 more
- Volunteers
- 371 people
- Sponsor
- University of North Carolina, Chapel Hill
HIV Infections
First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants
This FTIH study aims to evaluate the safety, tolerability and PK of the novel investigational Human immunodeficiency virus (HIV)-1 capsid inhibitor VH4011499 in healthy adults.
- Trial name
- NCT05393271
- Testing
- VH4011499, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Chlamydia Trachomatis, Neisseria Gonorrhoeae Infection
Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHER™ System
The objectives of this study are to establish the performance characteristics of the AC2 (APTIMA Combo 2) Assay on the PANTHER System for the sample types cleared for use on the TIGRIS and DTS (Direct Tube Sampling) Systems and…
- Trial name
- NCT01733069
- Testing
- APTIMA COMBO 2 Assay (AC2 Assay)
- Where
- 7 sites in United States
- Volunteers
- 1,912 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Hiv, Sexually Transmitted Diseases
Increasing HIV/STI Home Testing Via a Digital Intervention Among Black Women
The proposed intervention is a web-based intervention guided by theoretical components to increase HIV home testing among Black women at risk for HIV and sexually transmitted infections (STIs) in a HIV hotspot in the South.
- Conditions
- Hiv, Sexually Transmitted Diseases, Economic Problems
- Trial name
- NCT05390541
- Testing
- Empowered to Test Yourself, Educational Control
- Where
- 4 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Infection, Human Immunodeficiency Virus
Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
This 48 week, phase 2b study in 150 HIV-1 infected antiretroviral therapy experienced adult subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and 200 mg once daily with a control arm of…
- Trial name
- SONNET (NCT01199731)
- Testing
- GSK2248761 100 mg once daily, GSK2248761 200 mg once daily, Etravirine
- Where
- 41 sites in United States, Belgium and 3 more
- Volunteers
- 30 people
- Sponsor
- ViiV Healthcare
Sexually Transmitted Diseases
Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens
The study will determine tissue pharmacology of a single dose of doxycycline for sexually transmitted infection (STI) Post-exposure Prophylaxis (PEP).
- Trial name
- NCT04860505
- Testing
- Doxycycline, Biktarvy
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Emory University
HIV Infections, Staphylococcal Infections
Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons
This study will prospectively evaluate the prevalence and incidence (over a two year period) of MRSA colonization and infection among HIV-infected military beneficiaries to determine predictors for the development of MRSA…
- Trial name
- MRSA (NCT00631566)
- Testing
- Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%
- Where
- 4 sites in United States
- Volunteers
- 550 people
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
HIV Infection
Dual bNAb Treatment in Children
The purpose of this study is to evaluate the impact of two broadly neutralizing antibodies, VRC01LS and 10-1074, on the maintenance of HIV suppression in a cohort of early-treated children in Botswana.
- Trial name
- NCT03707977
- Testing
- ART, VRC01LS, 10-1074
- Where
- 2 sites in Botswana
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Genital Herpes
Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2
On 13 August 2008, this trial was submitted to ClinicalTrials.gov as modification to NCT00362297. On 28 April 2011, the two records were split for administrative purposes and each trial was given its own unique study record.
- Trial name
- NCT01346475
- Testing
- valacyclovir
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Infection, Human Immunodeficiency Virus, HIV Infections
Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)
The purpose of this study is to evaluate the long-term persistence of binding antibody responses against V1V2 and gp120 in subjects who were vaccinated with the envelope glycoprotein 120 (gp120)-negative factor (Nef)Tat/ Adjuvant…
- Trial name
- NCT03368053
- Testing
- Blood sampling
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C, HIV Infections
HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin
The primary objective of this study is to evaluate the safety and efficacy of a Response Guided Therapy of boceprevir 800 mg dosed three times a day (TID) orally (PO) in combination with Peginterferon (either alpha 2b or alpha…
- Conditions
- Hepatitis C, HIV Infections, COINFECTION
- Trial name
- BOC-HIV (NCT01718301)
- Testing
- boceprevir, Ribavirin, Peginterferon alfa-2a
- Where
- Spain
- Volunteers
- 108 people
- Sponsor
- Anna Cruceta
Heart Failure With Reduced Ejection Fraction, HIV Infections
Heart Failure Polypill at a Safety Net Hospital
A novel four-drug regimen for heart failure with reduced ejection fraction (HFrEF) extends patients' life expectancy by an average of 6 years compared to traditional therapies, in addition to improving quality of life.
- Trial name
- NCT06029712
- Testing
- Heart failure polypill, Control Rx
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of California, San Francisco
HIV Infections, Proteinuria
Pilot Study of Raltegravir Switch to Resolve Tenofovir Induced Proteinuria
The study is designed to evaluate the proportion of patients with tenofovir induced proteinuria that will resolve their proteinuria when the tenofovir containing nucleoside/nucleotide backbone is switched to a raltegravir…
- Trial name
- RALPIR (NCT01044771)
- Testing
- change from tenofovir to raltegravir
- Volunteers
- 20 people
- Sponsor
- Metropolis Medical
Kaposi's Sarcoma, HIV Positive
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
This is a pilot study to determine the efficacy, kinetics and safety of aldoxorubicin in HIV positive subjects with Kaposi's sarcoma.
- Conditions
- Kaposi's Sarcoma, HIV Positive, AIDS
- Trial name
- NCT02029430
- Testing
- 50 mg/m2 aldoxorubicin, 100 mg/m2 aldoxorubicin, 150 mg/m2 aldoxorubicin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- ImmunityBio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.